OraSure Technologies (OSUR) investor relations material

Strategic overview and operational progress

• Celebrating 25 years as a public company, with leading positions in rapid diagnostics and sample management.

• Focused on strengthening the core business, achieving break-even cash flow, and streamlining the portfolio.

• Diversified customer base to reduce reliance on public health funding and expanded into new channels.

• Strong governance with a refreshed, experienced board to guide future growth.

• 2025 marked as a transition year, navigating funding uncertainties while investing in innovation.

Product innovation and pipeline

• Near-term roadmap includes Sherlock CT/NG molecular test, Colli-Pee for STIs, and blood proteomics products.

• CT/NG test targets a $1.5B market, with FDA submission planned by early next year and potential launch mid-year.

• Platform approach enables future expansion into additional tests and applications.

• Investments in CRISPR detection and ambient temperature amplification aim to lower costs and improve performance.

• Recent acquisition of BioMedomics adds rapid sickle cell testing, leveraging existing international channels.

Financial position and capital allocation

• Maintains a strong cash position of $216 million as of Q3, supporting ongoing innovation and share repurchases.

• Announced a $40 million share buyback program over two years, reflecting confidence in long-term value.

• Core business is currently break-even; new product launches expected to drive profitability by 2027–2028.

• Focused on balancing innovation investment with operational efficiency to achieve 50%+ gross margins long term.

• Capital allocation prioritizes innovation, both organic and inorganic, with prudent acquisition strategies.